The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The biggest challenges in managing chronic pain in patients with SCD
In this video, Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, outlines the main challenges associated with managing chronic pain in patients with sickle cell disease (SCD), highlighting the need for improved understanding of the underlying causes of chronic pain and the importance of addressing mental health disorders in conjunction with pain management. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is a fantastic question because we really, as we are having more of these transformative therapies, it is addressing acute pain crises and it’s preventing really the admission to the hospital. And I am hopeful that we will be able to show improvement in some of the end-organ damage that has yet to be seen. But one of the challenges that remain in this patient population is many of them suffer from chronic pain due to the multiple vascular necrosis that they may have, and that is a phenomenon that we really have to better understand...
This is a fantastic question because we really, as we are having more of these transformative therapies, it is addressing acute pain crises and it’s preventing really the admission to the hospital. And I am hopeful that we will be able to show improvement in some of the end-organ damage that has yet to be seen. But one of the challenges that remain in this patient population is many of them suffer from chronic pain due to the multiple vascular necrosis that they may have, and that is a phenomenon that we really have to better understand. So the challenge is addressing that. It needs to be studied better in basic science. We need to understand more about why this chronic pain occurs and how to manage it better because this is not the same management as with opioids that we have. And we have as a physician, to treat this with empathy and to take the stigma out of that by having better research. But also, so many of these patients have mental health disorders, and that is really a problem in our healthcare system. So addressing the chronic pain has to be matched with also managing the mental health disorder and access to a therapist, either a psychologist or psychiatrist, to help us address that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sanofi: Consultancy; SOBI: Speakers Bureau; Vertex: Membership on an entity’s Board of Directors or advisory committees, Advisory Board; AbbVie: Consultancy.
